Darshan Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 31-07-2024
- Paid Up Capital ₹ 7.28 M
as on 31-07-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 7.70 Cr
as on 31-07-2024
- Revenue 50.14%
(FY 2023)
- Profit -58.67%
(FY 2023)
- Ebitda -21.97%
(FY 2023)
- Net Worth 32.21%
(FY 2023)
- Total Assets -20.66%
(FY 2023)
About Darshan Pharmachem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 7.28 M.
The company has closed loans amounting to ₹7.70 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Rasikkumar Dobaria, Jitendra Dobaria, Rasilaben Dobariya, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233GJ2013PTC077008
- Company No.
077008
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ankleshwar, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Darshan Pharmachem Private Limited offer?
Darshan Pharmachem Private Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Ketones, Chemical Reagents & Catalysts, Amine Compounds.
Who are the key members and board of directors at Darshan Pharmachem?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rasikkumar Dobaria  | Director | 30-Sep-2013 | Current |
| Jitendra Dobaria | Director | 30-Sep-2013 | Current |
| Rasilaben Dobariya | Director | 30-Sep-2013 | Current |
| Kenil Dobariya | Director | 06-May-2019 | Current |
Financial Performance of Darshan Pharmachem.
Darshan Pharmachem Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 50.14% increase. The company also saw a substantial fall in profitability, with a 58.67% decrease in profit. The company's net worth Soared by an impressive increase of 32.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Darshan Pharmachem?
In 2023, Darshan Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 04 Jul 2014 | ₹3.85 Cr | Satisfied |
State Bank Of India Creation Date: 04 Jul 2014 | ₹3.85 Cr | Satisfied |
How Many Employees Work at Darshan Pharmachem?
Unlock and access historical data on people associated with Darshan Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Darshan Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Darshan Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
